Gene Editing for Neurodegenerative Diseases

Gene Editing for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Gene Editing for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">[APP](/genes/app)</td>
<td>Reduce [Abeta](/proteins/amyloid-beta) production</td>
</tr>
<tr>
<td class="label">[PSEN1](/genes/psen1)</td>
<td>Correct familial AD mutations</td>
</tr>
<tr>
<td class="label">[PSEN2](/genes/psen2)</td>
<td>Correct mutations</td>
</tr>
<tr>
<td class="label">[APOE](/genes/apoe)</td>
<td>Convert APOE4 to APOE3</td>
</tr>
</table>

Gene Editing for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Gene Editing for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">[APP](/genes/app)</td>
<td>Reduce [Abeta](/proteins/amyloid-beta) production</td>
</tr>
<tr>
<td class="label">[PSEN1](/genes/psen1)</td>
<td>Correct familial AD mutations</td>
</tr>
<tr>
<td class="label">[PSEN2](/genes/psen2)</td>
<td>Correct mutations</td>
</tr>
<tr>
<td class="label">[APOE](/genes/apoe)</td>
<td>Convert APOE4 to APOE3</td>
</tr>
</table>

Gene editing technologies represent a transformative approach for treating neurodegenerative diseases by directly modifying disease-causing genetic mutations. Using tools like CRISPR-Cas9, base editing, and prime editing, researchers can correct pathogenic variants, reduce toxic protein expression, or modulate gene expression to halt or reverse disease progression. [@d2024]

Gene Editing Technologies

CRISPR-Cas9 Systems

The CRISPR-Cas9 system uses a guide RNA (gRNA) to direct the Cas9 nuclease to specific genomic loci for double-strand break formation: [@j2024]

Base Editing

Base editors enable precise single-nucleotide changes without double-strand breaks: [@m2023]

• Cytosine base editors (CBE) — Convert C→T or G→A
• Adenine base editors (ABE) — Convert A→G or T→C
• Prime editors — Enable all types of conversions and small insertions/deletions

Delivery Systems

• AAV vectors — Adeno-associated viruses for CNS delivery
• LNP (Lipid Nanoparticles) — Alternative delivery vehicles
• Viral vectors — Lentivirus, adenovirus for different applications

Applications in Neurodegenerative Diseases

Alzheimer's Disease

Gene editing targets: [@s2024]

Parkinson's Disease

Gene editing targets:

• [LRRK2](/genes/lrrk2) — Inhibit toxic gain-of-function mutations
• [SNCA](/genes/snca) — Reduce [α-synuclein](/proteins/alpha-synuclein) overexpression
• [PARK2 (Parkin)](/genes/parkin) — Restore function
• [PINK1](/genes/pink1) — Restore mitophagy function

Amyotrophic Lateral Sclerosis

Gene editing targets:

• [SOD1](/genes/sod1) — Silence toxic mutant SOD1
• [C9orf72](/genes/c9orf72) — Reduce toxic repeat expansions
• [FUS](/genes/fus) — Correct mutations
• [TARDBP](/genes/tardbp) — Address [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology

Huntington's Disease

Gene editing approaches:

• [HTT](/genes/htt) — Reduce mutant [huntingtin protein](/proteins/huntingtin)
• Allele-specific editing targeting mutant allele
• Non-allele-specific approaches

Clinical Development

Current Trials and Programs

Challenges

Therapeutic Strategies

Gene Silencing

• CRISPRi/dCas9-KRAB for transcriptional repression
• Guide RNA approaches for allele-specific silencing
• Combined with RNA interference

Gene Correction

• HDR-based correction of pathogenic mutations
• Base editing for precise nucleotide changes
• Prime editing for complex corrections

Gene Modulation

• Epigenetic editing to increase beneficial gene expression
• Protective allele introduction
• Regulatory element modification

Future Directions

Ethical Considerations

• Somatic vs. germline editing boundaries
• Equitable access to expensive therapies
• Informed consent for experimental treatments
• Long-term monitoring requirements

See Also

• [Antisense Oligonucleotide Therapies](/therapeutics/antisense-oligonucleotide-therapies)
• [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration)
• [CRISPR Technology](/technologies/crispr)
• [AAV Vectors](/technologies/aav-vectors-neurodegeneration)

External Links

• [ClinicalTrials.gov: Gene Editing](https://clinicaltrials.gov/search?cond=neurodegenerative+disease&intr=gene+editing)
• [American Society of Gene & Cell Therapy](https://www.asgct.org/)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring](/hypothesis/h-e23f05fb) — <span style="color:#ffd54f;font-weight:600">0.42</span> · Target: Disease-causing mutations with integrated reporters
• [Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: TARDBP
• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: TARDBP
• [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
• [Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: TARDBP
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;